XENCOR INC (XNCR) Stock Fundamental Analysis

NASDAQ:XNCR • US98401F1057

12.3 USD
-0.47 (-3.68%)
At close: Mar 2, 2026
12.3 USD
0 (0%)
After Hours: 3/2/2026, 4:30:02 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to XNCR. XNCR was compared to 520 industry peers in the Biotechnology industry. The financial health of XNCR is average, but there are quite some concerns on its profitability. XNCR is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

1

1. Profitability

1.1 Basic Checks

  • XNCR had negative earnings in the past year.
  • In the past year XNCR has reported a negative cash flow from operations.
  • XNCR had negative earnings in 4 of the past 5 years.
  • XNCR had negative operating cash flow in 4 of the past 5 years.
XNCR Yearly Net Income VS EBIT VS OCF VS FCFXNCR Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -100M -200M

1.2 Ratios

  • XNCR has a better Return On Assets (-15.97%) than 78.27% of its industry peers.
  • Looking at the Return On Equity, with a value of -22.19%, XNCR belongs to the top of the industry, outperforming 80.96% of the companies in the same industry.
Industry RankSector Rank
ROA -15.97%
ROE -22.19%
ROIC N/A
ROA(3y)-14.92%
ROA(5y)-8.95%
ROE(3y)-20.68%
ROE(5y)-12.58%
ROIC(3y)N/A
ROIC(5y)N/A
XNCR Yearly ROA, ROE, ROICXNCR Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10 -10 -20 -30

1.3 Margins

  • XNCR does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
XNCR Yearly Profit, Operating, Gross MarginsXNCR Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -50 -100 -150 -200

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

4

2. Health

2.1 Basic Checks

  • XNCR does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for XNCR has been increased compared to 1 year ago.
  • The number of shares outstanding for XNCR has been increased compared to 5 years ago.
  • Compared to 1 year ago, XNCR has an improved debt to assets ratio.
XNCR Yearly Shares OutstandingXNCR Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M
XNCR Yearly Total Debt VS Total AssetsXNCR Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M

2.2 Solvency

  • Based on the Altman-Z score of 1.31, we must say that XNCR is in the distress zone and has some risk of bankruptcy.
  • Looking at the Altman-Z score, with a value of 1.31, XNCR is in the better half of the industry, outperforming 63.27% of the companies in the same industry.
  • A Debt/Equity ratio of 0.14 indicates that XNCR is not too dependend on debt financing.
  • XNCR has a Debt to Equity ratio of 0.14. This is in the lower half of the industry: XNCR underperforms 63.08% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.14
Debt/FCF N/A
Altman-Z 1.31
ROIC/WACCN/A
WACC8.07%
XNCR Yearly LT Debt VS Equity VS FCFXNCR Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M 400M 600M

2.3 Liquidity

  • XNCR has a Current Ratio of 5.99. This indicates that XNCR is financially healthy and has no problem in meeting its short term obligations.
  • With a decent Current ratio value of 5.99, XNCR is doing good in the industry, outperforming 61.92% of the companies in the same industry.
  • XNCR has a Quick Ratio of 5.99. This indicates that XNCR is financially healthy and has no problem in meeting its short term obligations.
  • XNCR has a Quick ratio of 5.99. This is in the better half of the industry: XNCR outperforms 63.08% of its industry peers.
Industry RankSector Rank
Current Ratio 5.99
Quick Ratio 5.99
XNCR Yearly Current Assets VS Current LiabilitesXNCR Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

5

3. Growth

3.1 Past

  • XNCR shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 44.69%, which is quite impressive.
  • XNCR shows a strong growth in Revenue. In the last year, the Revenue has grown by 96.51%.
  • The Revenue has been decreasing by -6.75% on average over the past years.
EPS 1Y (TTM)44.69%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%88.73%
Revenue 1Y (TTM)96.51%
Revenue growth 3Y-26.22%
Revenue growth 5Y-6.75%
Sales Q2Q%96.07%

3.2 Future

  • XNCR is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 10.41% yearly.
  • The Revenue is expected to grow by 38.69% on average over the next years. This is a very strong growth
EPS Next Y46.57%
EPS Next 2Y9.56%
EPS Next 3Y9.69%
EPS Next 5Y10.41%
Revenue Next Year113.06%
Revenue Next 2Y41.62%
Revenue Next 3Y28.84%
Revenue Next 5Y38.69%

3.3 Evolution

  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
XNCR Yearly Revenue VS EstimatesXNCR Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 500M 1B 1.5B
XNCR Yearly EPS VS EstimatesXNCR Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 0 2 -2 4

More info and screens

Find the best growth stocksShow best growing peers

0

4. Valuation

4.1 Price/Earnings Ratio

  • XNCR reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for XNCR. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
XNCR Price Earnings VS Forward Price EarningsXNCR Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
XNCR Per share dataXNCR EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 6 8

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y9.56%
EPS Next 3Y9.69%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • XNCR does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

XENCOR INC

NASDAQ:XNCR (3/2/2026, 4:30:02 PM)

After market: 12.3 0 (0%)

12.3

-0.47 (-3.68%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-05
Earnings (Next)03-04
Inst Owners119.02%
Inst Owner Change3.61%
Ins Owners1.12%
Ins Owner Change0.27%
Market Cap878.34M
Revenue(TTM)167.36M
Net Income(TTM)-138.75M
Analysts84
Price Target29.41 (139.11%)
Short Float %15.5%
Short Ratio15.44
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)66.4%
Min EPS beat(2)44.19%
Max EPS beat(2)88.61%
EPS beat(4)3
Avg EPS beat(4)36.93%
Min EPS beat(4)-7.54%
Max EPS beat(4)88.61%
EPS beat(8)4
Avg EPS beat(8)-15.47%
EPS beat(12)7
Avg EPS beat(12)0.09%
EPS beat(16)10
Avg EPS beat(16)90.88%
Revenue beat(2)1
Avg Revenue beat(2)37.58%
Min Revenue beat(2)-24.18%
Max Revenue beat(2)99.34%
Revenue beat(4)3
Avg Revenue beat(4)74.2%
Min Revenue beat(4)-24.18%
Max Revenue beat(4)165.74%
Revenue beat(8)3
Avg Revenue beat(8)22.23%
Revenue beat(12)6
Avg Revenue beat(12)26.44%
Revenue beat(16)9
Avg Revenue beat(16)40.88%
PT rev (1m)0%
PT rev (3m)3.31%
EPS NQ rev (1m)0%
EPS NQ rev (3m)3.97%
EPS NY rev (1m)0%
EPS NY rev (3m)27.16%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)3.03%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-2.79%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 5.25
P/FCF N/A
P/OCF N/A
P/B 1.4
P/tB 1.43
EV/EBITDA N/A
EPS(TTM)-1.77
EYN/A
EPS(NY)-2.81
Fwd EYN/A
FCF(TTM)-2.01
FCFYN/A
OCF(TTM)-1.95
OCFYN/A
SpS2.34
BVpS8.76
TBVpS8.62
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -15.97%
ROE -22.19%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-14.92%
ROA(5y)-8.95%
ROE(3y)-20.68%
ROE(5y)-12.58%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.19
Health
Industry RankSector Rank
Debt/Equity 0.14
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 42.94%
Cap/Sales 2.8%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 5.99
Quick Ratio 5.99
Altman-Z 1.31
F-Score3
WACC8.07%
ROIC/WACCN/A
Cap/Depr(3y)252.19%
Cap/Depr(5y)241.55%
Cap/Sales(3y)15.72%
Cap/Sales(5y)12.84%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)44.69%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%88.73%
EPS Next Y46.57%
EPS Next 2Y9.56%
EPS Next 3Y9.69%
EPS Next 5Y10.41%
Revenue 1Y (TTM)96.51%
Revenue growth 3Y-26.22%
Revenue growth 5Y-6.75%
Sales Q2Q%96.07%
Revenue Next Year113.06%
Revenue Next 2Y41.62%
Revenue Next 3Y28.84%
Revenue Next 5Y38.69%
EBIT growth 1Y44.9%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year31.42%
EBIT Next 3Y12.89%
EBIT Next 5Y10.61%
FCF growth 1Y4.79%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-15.34%
OCF growth 3YN/A
OCF growth 5YN/A

XENCOR INC / XNCR FAQ

Can you provide the ChartMill fundamental rating for XENCOR INC?

ChartMill assigns a fundamental rating of 3 / 10 to XNCR.


Can you provide the valuation status for XENCOR INC?

ChartMill assigns a valuation rating of 0 / 10 to XENCOR INC (XNCR). This can be considered as Overvalued.


Can you provide the profitability details for XENCOR INC?

XENCOR INC (XNCR) has a profitability rating of 1 / 10.


Can you provide the expected EPS growth for XNCR stock?

The Earnings per Share (EPS) of XENCOR INC (XNCR) is expected to grow by 46.57% in the next year.